Biblio

Tang X, Brinton RDiaz, Chen Z, Farland LV, Klimentidis Y, Migrino R, Reaven P, Rodgers K, Zhou JJ.  2022.  Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.. BMJ Open Diabetes Res Care. 10(5)

Zissimopoulos JM, Barthold D, Brinton RDiaz, Joyce G.  2017.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease.. JAMA Neurol. 74(2):225-232.

Karim R, Dang H, Henderson VW, Hodis HN, St John J, Brinton RD, Mack WJ.  2016.  Effect of Reproductive History and Exogenous Hormone Use on Cognitive Function in Mid- and Late Life.. J Am Geriatr Soc. 64(12):2448-2456.

Rettberg JR, Dang H, Hodis HN, Henderson VW, St John JA, Mack WJ, Brinton RDiaz.  2016.  Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.. Neurobiol Aging. 40:155-63.

Karim R, Stanczyk FZ, Brinton RD, Rettberg J, Hodis HN, Mack WJ.  2015.  Association of endogenous sex hormones with adipokines and ghrelin in postmenopausal women.. J Clin Endocrinol Metab. 100(2):508-15.

Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur M-E, Besançon R et al..  2015.  CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.. Cancer Res. 75(17):3519-28.

Espeland MA, Brinton RDiaz, Hugenschmidt C, Manson JAE, Craft S, Yaffe K, Weitlauf J, Vaughan L, Johnson KC, Padula CB et al..  2015.  Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women.. Diabetes Care. 38(12):2316-24.

Espeland MA, Brinton RDiaz, Manson JAE, Yaffe K, Hugenschmidt C, Vaughan L, Craft S, Edwards BJ, Casanova R, Masaki K et al..  2015.  Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes.. Neurology. 85(13):1131-8.

White AG, Watts GS, Lu Z, Meza-Montenegro MM, Lutz EA, Harber P, Burgess JL.  2014.  Environmental arsenic exposure and microbiota in induced sputum.. Int J Environ Res Public Health. 11(2):2299-313.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS et al..  2009.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.

D Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.  2005.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.. Arch Neurol. 62(5):753-7.

D Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J et al..  2005.  Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.. Curr Alzheimer Res. 2(3):343-53.